Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + Lenalidomide + Dexamethasone in Japanese RRMM
NCT02917941Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by Takeda. Primary endpoint: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response up to 33 months. Started Nov 2016; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02917941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917941.